ChemotherapyFDA-approvedFirst-line
Xeloda
Generic name: capecitabine
How it works
Is converted into 5-fluorouracil, which interferes with DNA replication and causes cell death in rapidly dividing cancer cells.
Cancer types
Colorectal Cancer— All patients
Efficacy
In clinical trials, Xeloda improved response rates and progression-free survival in patients with metastatic colorectal cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Study Examines Effectiveness of Capecitabine in Early-Stage Triple-Negative Breast Cancer | Breast Cancer | observational | Survival rates from surgery to 36 months were numerically lower in patients with BRCAm versus non-BRCAm (invasive disease-free survival: 59% vs. 72%; distant disease-free survival: 59% vs. 73%; overall survival: 67% vs. 80%). | Source → |
| Monitoring Cancer DNA During Treatment in Early Triple-Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Metronomic Chemotherapy May Help Manage Advanced Breast Cancer | Breast Cancer | observational | The median time-to-next treatment or death was 22.0 weeks. | Source → |
| Galunisertib and Capecitabine Combination for Advanced Colorectal Cancer | Colorectal Cancer | phase-1 | — | Source → |
| Pyrotinib Plus Capecitabine May Improve Survival in HER2-Positive Breast Cancer | Breast Cancer | phase-3 | Median overall survival was 74.61 months with pyrotinib plus capecitabine and 30.98 months with lapatinib plus capecitabine. | Source → |
| Testing a New Combination Therapy for ER+ Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing a New Treatment for Advanced Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Testing Capecitabine in ER+ Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing Capecitabine for Metastatic ER Positive Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Rectal Cancer Trial Examines New Treatment Combination | Colorectal Cancer | phase-2 | — | Source → |
| Testing Atezolizumab and Capecitabine for Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Combination Therapy Shows Promise for Advanced Breast Cancer | Breast Cancer | phase-2 | The objective response rate was 25.8%, with 17 partial responses. | Source → |
| Evaluating a Combination Treatment for Metastatic Colorectal Cancer in Elderly Patients | Colorectal Cancer | phase-2 | — | Source → |
| Study Examines Effectiveness of Capecitabine in Triple-Negative Breast Cancer | Breast Cancer | observational | Adjuvant capecitabine did not improve disease-free survival (HR = 0.96; 95% CI 0.52-1.78) or overall survival (HR = 0.70; 95% CI 0.33-1.46) in univariable analyses. | Source → |
| Genetic Testing for Breast Cancer Patients on Capecitabine May Be Cost-Effective | Breast Cancer | phase-3 | The genotyping strategy yielded 1.16 QALYs at a cost of $2,832, compared to $2,677 and 1.15 QALYs for the no-genotyping strategy. | Source → |
| New Treatment Combination for Triple-Negative Breast Cancer Being Tested | Breast Cancer | phase-3 | — | Source → |
| Testing Tetrathiomolybdate and Capecitabine for Triple Negative Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Methylcobalamin May Help Prevent Hand-Foot Syndrome in Breast Cancer Patients | Breast Cancer | phase-3 | Grade ≥2 hand-foot syndrome occurred in 14.5% of patients in the methylcobalamin group, compared to 29.1% in the placebo group. | Source → |
| Capecitabine plus Temozolomide Therapy for Pancreatic Tumors | Pancreatic Cancer | observational | The objective response rates and disease control rates were 26.7 and 66.7%, respectively. | Source → |
| Lu-DOTATATE with Capecitabine Tested in Advanced Gastroenteropancreatic Neuroendocrine Tumors | Pancreatic Cancer | phase-2 | The objective response rate was 33.3% in the experimental arm versus 30.6% in the control arm. | Source → |
| Predicting Capecitabine-Induced Diarrhea in Cancer Patients | Colorectal Cancer | lab-study | The area under curve of the model was 0.907, with a specificity of 100.0% and a sensitivity of 71.4% for predicting diarrhea in colorectal cancer patients. | Source → |
| New Treatment Options for Advanced HER2-Positive Breast Cancer | Breast Cancer | phase-3 | Median overall survival for patients in the tucatinib arm was 21.9 months compared with 17.4 months for patients in the control arm. | Source → |
| Long-Term Outcomes of Pancreatic Cancer Treatment | Pancreatic Cancer | phase-3 | The median overall survival was 31.6 months in patients given GemCap. | Source → |
| Phenytoin Interaction with Capecitabine in Cancer Treatment | Colorectal Cancer | observational | — | Source → |
| Tailoring Cancer Treatment for Triple-Negative Breast Cancer Patients | Breast Cancer | phase-3 | Among immune-hot patients, the 5-year disease-free survival rate was 96.9% in the capecitabine group and 79.4% in the control group. | Source → |
| Neoadjuvant Chemotherapy for Rare Lung Tumors Shows Promise | Lung Cancer | observational | There was a 21% regression in the primary tumor size. | Source → |
| Combining two treatments for hormone receptor positive breast cancer | Breast Cancer | phase-2 | The estimated median progression-free survival for the combination was 17.7 months versus 14.6 months for letrozole alone. | Source → |
| Targeted Cancer Treatment Using Carbohydrate-Based Nanoparticles | Colorectal Cancer | lab-study | — | Source → |
| Rare Case of Ependymoma Shows Long-Term Remission with Combination Chemotherapy | Lung Cancer | observational | The patient remained in remission for approximately 29 months. | Source → |
| Chemotherapy for Colon Cancer: How Many Cycles Matter? | Colorectal Cancer | observational | Patients belonging to group C were found to have a trend for lower relapse rate compared to patients belonging to group A or group B. | Source → |
| Capecitabine Maintenance Therapy for Early-Stage Triple-Negative Breast Cancer | Breast Cancer | phase-3 | Compared with routine follow-up, 1-year capecitabine maintenance therapy yielded an additional 1.29 quality-adjusted life years (QALYs) at an additional cost of $3391.70. | Source → |
| Restricting Certain Amino Acids May Help Treat Colon Cancer | Colorectal Cancer | animal-study | Mice fed diet TC5 lived longer than untreated mice in both models. | Source → |
| New Treatment Combination Shows Promise for Advanced Breast Cancer | Breast Cancer | phase-3 | Treatment with pyrotinib plus capecitabine significantly improved overall survival compared with lapatinib plus capecitabine. | Source → |
| Combining Bevacizumab and Capecitabine May Help Some Colorectal Cancer Patients | Colorectal Cancer | observational | The median progression-free survival was 9.0 months in the observation group and 7.2 months in the control group. | Source → |
| New Soaking Solution May Help Relieve Hand-Foot Syndrome in Breast Cancer Patients | Breast Cancer | phase-2 | The HFS effectiveness rate was 80% in the treated group and 51.7% in the placebo group. | Source → |
| Oral Capecitabine May Be Better Than IV 5-Fluorouracil for Rectal Cancer | Colorectal Cancer | phase-3 | Complete tumour regression occurred in 25.3% after oral- and 13.8% after intravenous treatment. | Source → |
| Combining Capecitabine and Oxaliplatin for Colorectal Cancer Treatment | Colorectal Cancer | observational | The overall response rate was 69.6% with 13 patients attaining a complete response. | Source → |
| Understanding Drug Interactions in Cancer Treatment | Colorectal Cancer | animal-study | — | Source → |
| Lapatinib Efficacy in HER2 Positive Breast Cancer Patients | Breast Cancer | phase-2 | Median overall survival was 10.1 months in the group that received lapatinib after exposure to trastuzumab, pertuzumab and/or T-DM1, and 16.3 months in the group of patients who received lapatinib after trastuzumab. | Source → |
| Adding Oxaliplatin to Rectal Cancer Treatment Does Not Improve Outcomes | Colorectal Cancer | phase-3 | Three-year disease-free survival was 76.3% for the capecitabine with RT group and 74.1% for the capecitabine and oxaliplatin with RT group. | Source → |
| Colorectal Cancer Treatment Trends in China | Colorectal Cancer | observational | — | Source → |
| Tucatinib Shows Promise for HER2-Positive Breast Cancer | Breast Cancer | meta-analysis | — | Source → |
| Sequential Treatment for Pancreatic Neuroendocrine Tumors | Pancreatic Cancer | observational | The objective response rate with second-line treatment was higher in one group (21.1%) than in the other (5.3%). | Source → |
| Comparing Chemotherapy Options for Pancreatic Cancer | Pancreatic Cancer | review | FOLFIRINOX had significantly better overall survival (OS) and relapse-free survival (RFS)/disease-free survival (DFS)/progression-free survival (PFS) compared to gem-cap and gem-nab/P. | Source → |
| Metronomic Chemotherapy Shows Promise in Advanced Breast Cancer | Breast Cancer | observational | The median progression-free survival for the capecitabine-based group was 8.9 months, compared to 5.9 months for the other metronomic chemotherapy group. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.